141 related articles for article (PubMed ID: 27823573)
41. Potential sphingosine-1-phosphate-related therapeutic targets in the treatment of cerebral ischemia reperfusion injury.
Han M; Sun T; Chen H; Han M; Wang D
Life Sci; 2020 May; 249():117542. PubMed ID: 32169519
[TBL] [Abstract][Full Text] [Related]
42. Beneficial Effects of Fingolimod in Alzheimer's Disease: Molecular Mechanisms and Therapeutic Potential.
Angelopoulou E; Piperi C
Neuromolecular Med; 2019 Sep; 21(3):227-238. PubMed ID: 31313064
[TBL] [Abstract][Full Text] [Related]
43. Lessons from S1P receptor targeting in multiple sclerosis.
Colombo E; Farina C
Pharmacol Ther; 2022 Feb; 230():107971. PubMed ID: 34450231
[TBL] [Abstract][Full Text] [Related]
44. Sphingosine-1-phosphate modulators in inflammatory skin diseases - lining up for clinical translation.
Thieme M; Zillikens D; Sadik CD
Exp Dermatol; 2017 Mar; 26(3):206-210. PubMed ID: 27574180
[TBL] [Abstract][Full Text] [Related]
45. Sphingosine 1-Phosphate Receptors in Cerebral Ischemia.
Gaire BP; Choi JW
Neuromolecular Med; 2021 Mar; 23(1):211-223. PubMed ID: 32914259
[TBL] [Abstract][Full Text] [Related]
46. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
47. Sphingosine-1-phosphate signaling: A novel target for simultaneous adjuvant treatment of triple negative breast cancer and chemotherapy-induced neuropathic pain.
Singh SK; Spiegel S
Adv Biol Regul; 2020 Jan; 75():100670. PubMed ID: 31708456
[TBL] [Abstract][Full Text] [Related]
48. The S1P-S1PR Axis in Neurological Disorders-Insights into Current and Future Therapeutic Perspectives.
Lucaciu A; Brunkhorst R; Pfeilschifter JM; Pfeilschifter W; Subburayalu J
Cells; 2020 Jun; 9(6):. PubMed ID: 32580348
[TBL] [Abstract][Full Text] [Related]
49. Sphingosine 1-phosphate signaling impacts lymphocyte migration, inflammation and infection.
Tiper IV; East JE; Subrahmanyam PB; Webb TJ
Pathog Dis; 2016 Aug; 74(6):. PubMed ID: 27354294
[TBL] [Abstract][Full Text] [Related]
50. Integrated sphingosine-1 phosphate signaling in the central nervous system: From physiological equilibrium to pathological damage.
Ghasemi R; Dargahi L; Ahmadiani A
Pharmacol Res; 2016 Feb; 104():156-64. PubMed ID: 26772814
[TBL] [Abstract][Full Text] [Related]
51. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
52. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
Pérez-Jeldres T; Alvarez-Lobos M; Rivera-Nieves J
Drugs; 2021 Jun; 81(9):985-1002. PubMed ID: 33983615
[TBL] [Abstract][Full Text] [Related]
53. The role of sphingosine 1-phosphate metabolism in brain health and disease.
van Echten-Deckert G
Pharmacol Ther; 2023 Apr; 244():108381. PubMed ID: 36907249
[TBL] [Abstract][Full Text] [Related]
54. Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
Peyrin-Biroulet L; Christopher R; Behan D; Lassen C
Autoimmun Rev; 2017 May; 16(5):495-503. PubMed ID: 28279838
[TBL] [Abstract][Full Text] [Related]
55. Sphingosine-1-Phosphate Signaling in Immune Cells and Inflammation: Roles and Therapeutic Potential.
Aoki M; Aoki H; Ramanathan R; Hait NC; Takabe K
Mediators Inflamm; 2016; 2016():8606878. PubMed ID: 26966342
[TBL] [Abstract][Full Text] [Related]
56. Sphingosine-1 phosphate and central nervous system.
Martin R; Sospedra M
Curr Top Microbiol Immunol; 2014; 378():149-70. PubMed ID: 24728597
[TBL] [Abstract][Full Text] [Related]
57. Targeting sphingosine-1-phosphate signaling for cancer therapy.
Xie Z; Liu H; Geng M
Sci China Life Sci; 2017 Jun; 60(6):585-600. PubMed ID: 28623546
[TBL] [Abstract][Full Text] [Related]
58. Preclinical and Clinical Evidence for the Involvement of Sphingosine 1-Phosphate Signaling in the Pathophysiology of Vascular Cognitive Impairment.
Chua XY; Ho LTY; Xiang P; Chew WS; Lam BWS; Chen CP; Ong WY; Lai MKP; Herr DR
Neuromolecular Med; 2021 Mar; 23(1):47-67. PubMed ID: 33180310
[TBL] [Abstract][Full Text] [Related]
59. Central effects of fingolimod.
Cruz VT; Fonseca J
Rev Neurol; 2014 Aug; 59(3):121-8. PubMed ID: 25030072
[TBL] [Abstract][Full Text] [Related]
60. Sphingosine-1-phosphate signaling in physiology and diseases.
Takuwa Y; Okamoto Y; Yoshioka K; Takuwa N
Biofactors; 2012; 38(5):329-37. PubMed ID: 22674845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
